Mad Money 09/08/26 | Audio Only
Speakers
Jim Cramer
— Host, Mad Money
Matt Murphy
— Chairman and CEO, Marvell Technology, Inc.
Spencer
— Caller
Summary
Jim Cramer argues investors are too obsessed with data centers and highlights opportunities in aerospace, healthcare, energy infrastructure, consumer finance, and select technology names. He builds a fantasy-stock-football portfolio with names such as Apple, Nvidia, Eli Lilly, Amazon, Palantir, SpaceX, Merck, and Chevron. Later, Marvell CEO Matt Murphy presents a bullish custom-silicon and optical-connectivity growth story. Cramer also discusses market supply risks from IPOs and lockups, and gives several rapid-fire calls on individual stocks.
- Cramer sees data center names as vulnerable near-term but remains positive on several specific power and semiconductor stories after the election.
- He highlights aerospace strength via GE Aerospace's supply-chain acquisition and Boeing's improving setup.
- He names Robinhood, Affirm, Hinge Health, Medtronic, and Amgen as non-data-center opportunities.
- He recommends energy income names including Enbridge, Enterprise Products Partners, and refiners Valero and Marathon.
- In his fantasy stock football segment, he picks Apple, Nvidia, Eli Lilly, Medline, Palantir, Amazon, Dell, Hinge Health, SpaceX, Merck, and Chevron.
- Marvell CEO Matt Murphy argues the company is a trusted custom-silicon and optical-connectivity leader with big hyperscaler relationships.
- Cramer warns that upcoming IPO and lockup supply could pressure the broad stock market unless M&A consolidation accelerates.
Ideas
GE Vernova benefits from data center power
Cramer says he is not abandoning data center-related power names. He specifically cites GE Vernova, which makes turbines that turn natural gas into electricity, as a position he still owns because of data center power demand.
Intel CPU pricing power from tight supply
Cramer says Intel makes CPUs and is raising prices on them because demand is much greater than supply.
Micron bought for charitable trust
Cramer says the charitable trust just bought Micron after visiting its world headquarters in Boise, Idaho, signaling conviction in improving memory demand tied to the data center buildout.
GE Aerospace supply chain deal boosts output
GE Aerospace is buying Consolidated Precision Products to integrate a key casting segment into its supply chain. Cramer says this is vital for booming commercial aircraft and defense businesses and should pay off quickly by helping GE accelerate production.
Boeing order book and supply chain improving
Cramer says GE's supply chain acquisition is also good news for Boeing, a huge customer. Boeing's order book is full, the Spirit AeroSystems problems are behind it, and higher jet fuel makes new energy-efficient planes and engines more valuable.
Robinhood owns youth market deposits
Robinhood owns the youth market: three-quarters of clients are under 45, median age is 35, deposits are growing at a 28% clip, and funded customers total 28.4 million. Cramer says crypto and prediction market excitement is just the big picture behind the stock's run.
Affirm quarter momentum, holiday upside
Affirm just reported an excellent quarter and has 28 million active customers with partners including Amazon, Costco, Shopify, Target, and Apple. Cramer says the stock is being sold on Fed rate hike fears, but the quarter had enough momentum for strong numbers through the holiday season.
Hinge Health profitable telehealth compounder
Hinge Health is a digital physical therapy company in bull market mode. Employers and managed care companies pay for its services because it is cheaper and more convenient than traditional physical therapy. It is growing revenue nearly 50%, is profitable, and still trades at 40 times earnings after tripling from February lows.
Medtronic organic growth surprise, stock flat
Medtronic delivered a big upside surprise and a major increase in organic growth, and it is separating its worrisome diabetes division. Yet the stock is still where it was before reporting despite a vastly improved business, which Cramer says is crazy.
Refiners benefit while Iran war persists
As long as the war with Iran drags on, Cramer says it is easy to recommend the refiners like Valero and Marathon because the conflict shows no sign of ending soon.
Enbridge high yield energy infrastructure
Enbridge moves about 30% of all crude produced in North America and transports 20% of the natural gas consumed in America. It yields 5.5%, and Cramer says it is not caught in the tariff fight because tariffs on Canadian energy would be economic suicide for the US.
Enterprise Products Partners war-driven margins
Enterprise Products Partners may be the single biggest pipeline winner from the war, according to Cramer. CEO Jim Teague says the Hormuz closure has boosted margins on liquids like ethane-to-ethylene and ethylene-to-polyethylene, and the Houston Ship Channel is now as important as the Strait of Hormuz. The stock yields 5.8%.
Amgen derisked after drug selloff
Amgen fell on read-through from a failed Novartis cardiovascular drug, but Cramer says Amgen's similar candidate is slightly different and won't read out until 2027 or 2028. After the decline, Amgen could remove that drug from the portfolio and the stock probably would not go down much more.
Data center stocks vulnerable pre-election
Cramer says the endless focus on data centers and the anti-data-center backlash will make for rough sledding between now and the election. He recommends selling many data center stories into strength and not loading up on the group near term.
Dell preferred over SMCI accounting risk
Cramer says SMCI has accounting irregularities and cannot be recommended despite its momentum. He prefers Dell Technologies, which he has been recommending as better than Super Micro and still attractive even after its big run on AI server demand.
Dell preferred over SMCI accounting risk
Cramer says SMCI has accounting irregularities and cannot be recommended despite its momentum. He prefers Dell Technologies, which he has been recommending as better than Super Micro and still attractive even after its big run on AI server demand.
Apple lower risk AI partner model
Apple is Cramer's fantasy stock quarterback and an own-it-don't-trade-it name. Apple makes beloved products, spends almost nothing on AI, and instead partners with AI companies that need access to its massive user base. That makes Apple less risky than other mega-cap peers.
Nvidia mature compounder, own don't trade
Nvidia is an own-it-don't-trade-it compounder. It is still on track for 70% revenue growth next year, and its advanced computing platform combines chips, networking equipment, and software. Cramer says Nvidia remains one of the first stocks someone should buy when building a portfolio.
Eli Lilly GLP-1 value opportunity
Eli Lilly has become a great compounder thanks to its booming GLP-1 weight loss business. The stock trades at just over 30 times earnings, down from 45 times at the start of the year, which Cramer says represents decent value.
Medline post-IPO sleeper compounding opportunity
Medline, the largest IPO of 2025, is a distributor of medical surgical products. After a hot start, the stock pulled back from the low 50s to the mid-30s due partly to a warehouse fire, but Cramer says that is temporary and Medline could be a long-term compounder and sleeper.
Palantir explosive growth, expensive but working
Palantir is a pure growth stock that recently posted a magnificent quarter and rallied more than 60% from its lows. It is not cheap at more than 100 times this year's earnings estimates, but Cramer says few stocks have been better when it works.
Amazon AWS strength at 20x earnings
Amazon's AWS business is on fire, and the stock has gotten cheaper at 20 times this year's earnings estimates. Cramer calls it a sleep-at-night growth stock that is more dependable than higher-upside options.
SpaceX multi-business growth, speculative
SpaceX is Cramer's flex pick because it is hard to put in one box: rockets, Starlink satellite internet, and AI. Shareholders want growth points on the board. He acknowledges it may take longer to pay off, the company is losing money, the stock trades around 50 times sales, and restricted shares are unlocking soon.
Merck defensive drug stock with upside
Merck fits the defensive stock role because it does fine even in a bad economy or if the Fed hikes rates. It also has upside from partner Moderna's promising melanoma vaccine results. The stock is up 41% year to date, though it faces a clock on Keytruda patent expirations.
Chevron oil upside plus dividend yield
Chevron is Cramer's kicker equivalent: an energy stock that usually does not trade with the rest of the market and offers a 3.4% yield. With oil prices rising this year, Chevron is up nearly 40% and can provide surprise upside like a kicker hitting long field goals.
Lululemon execution poor, more downside
Cramer says Lululemon is executing really poorly. Even at 10 times earnings, he does not trust that it will make those earnings. He does not like the stock here and says it could fall from around 103 to maybe 85.
Marvell custom silicon and connectivity leader
Marvell's CEO says fears about competition were overblown. The company raised its outlook from $10 billion this year and $13.5 billion next year to $12 billion and $18 billion. It has partnerships with Nvidia and Google, custom silicon relationships with all four big hyperscalers, and leadership in optical connectivity. Management bought stock in the mid-70s as a sign of conviction.
Joby too much cash burn
Cramer is against Joby Aviation because it is losing a lot of money. He calls it an interesting speculation but says he would not put his money in it.
Steel shortage favors Reliance and Nucor
Cramer says Reliance Steel is terrific and a very good company, and he prefers Nucor. The caller notes steel shortages and RS outperforming the S&P 500.
Mall REITs deliver attractive yields
Cramer says Simon Property Group is great with a 4.25% yield, and he also likes Federal Realty. Both are excellent retail real estate income names.
Grab speculative, can go to zero
Cramer says he has never liked Grab Holdings and does not think it is worth investing in. At around $3, he calls it a $3 speculation and warns that stocks can go to zero.
Trinity railcar pullback is buyable
Cramer says Trinity Industries should not be down this much. He likes the caller's thinking that the railcar stock has pulled back and says he would pull the trigger at this level.
AstraZeneca trial misses, avoid
Cramer is nervous about AstraZeneca because it has been missing some trials. He does not think the COPD opportunity is enough to change his mind and would not put his money on the stock.
New supply risks stock market
Cramer says the market needs consolidation because too much new stock supply is coming: SpaceX lockup expirations, potential IPOs from Oura, SP Energy, Wella, Anthropic, and OpenAI. With 30-year paper yielding 5.2%, there is serious competition for stock market cash, and too much new supply without enough cash can stop a bull market.
Up Next
This CNBC video, published September 09, 2026, features Jim Cramer, Matt Murphy discussing GEV, INTC, MU, GE, BA, HOOD, AFRM, Hinge Health, MDT, VLO, MPC, ENB, EPD, AMGN, DATA CENTER STOCKS, DELL, SMCI, AAPL, NVDA, LLY, MDL, PLTR, AMZN, SPCX, MRK, CVX, LULU, MRVL, JOBY, RS, NUE, FRT, SPG, GRAB, TRN, AZN, SPY. 34 trade ideas extracted by AI with direction and confidence scoring.
Speakers: Jim Cramer, Matt Murphy · Tickers: GEV, INTC, MU, GE, BA, HOOD, AFRM, Hinge Health, MDT, VLO, MPC, ENB, EPD, AMGN, DATA CENTER STOCKS, DELL, SMCI, AAPL, NVDA, LLY, MDL, PLTR, AMZN, SPCX, MRK, CVX, LULU, MRVL, JOBY, RS, NUE, FRT, SPG, GRAB, TRN, AZN, SPY